Jonathan Jackson is not exactly dominating the Sunday shows. Zero Google News stories in the last 24 hours, three Bluesky posts that include a Nashville TV series listing and a Wikipedia edit notification. The social footprint of a man actively avoiding the spotlight. Which makes the disclosure filings more interesting, not less. Nine trades in 90 days, a $50K–00K Visa sale the same week two banking bills sailed through the House without his vote, and a career alpha record that sits at exactly dead-even: 48 positive outcomes out of 97 scored trades, mean 30-day alpha of essentially zero. The congressman from Illinois's 1st district is not a headline. He's a filing.
The Visa Sale
On April 24, per his disclosure record on Blind Trust, Jackson sold between $50,000 and 00,000 worth of Visa stock. The single largest trade in the 90-day window. It also carries a committee-overlap flag.
Jackson sits on the House Financial Services Committee. Visa is a financial services company. The overlap is not a technicality you have to squint to see.
The 30-day alpha on that Visa sale was negative 0.3%, so the trade didn't print. The timing, not the return, is what lands the committee jurisdiction and the position size in the same sentence.
Members are required to disclose. They are not required to divest, recuse, abstain, or look up from their phones.
Banking Bills, Absent Votes
Three weeks after the Visa sale, on May 20, the House passed four bills in a single session. Jackson was not voting on any of them.
Two of those bills carry a market relevance score of 95 out of 100 in our data: the American Access to Banking Act (H.R. 4544) and the Community Bank Deposit Access Act of 2025 (H.R. 5317). Both passed. The Keeping Deposits Local Act (H.R. 3234) also passed that day, also without Jackson's vote.
Three banking-sector bills. One Financial Services Committee member. Zero votes cast.
There is no flagged vote-trade overlap in our system connecting the Visa sale to those absences — the dates don't align as a clean before-and-after. But the calendar is uncomfortable: sell the financial services position in late April, skip the financial services votes in late May. The interpretation is yours.
The Other April Trades
The Visa sale was not the only move on April 24. The same day, Jackson also sold K–5K in O'Reilly Automotive (ORLY) — the second ORLY sale in 90 days. He had trimmed another 5K–$50K slice of O'Reilly on March 19. Auto parts retail, recurring, being wound down.
Four days before the April 24 sales, on April 20, he bought 5K–$50K in Procter & Gamble and sold 5K–$50K in Tenet Healthcare (THC). He had already sold a smaller THC position on April 15 (K–5K). Two Tenet Healthcare sales in nine days, total exposure reduced somewhere in the 6K–$65K range depending on where those brackets land.
Tenet Healthcare is a for-profit hospital operator. The political environment for that sector in spring 2026 is not a warm bath. Draw your own line.
BP in March
In mid-March, Jackson was accumulating BP. A 5K–$50K purchase on March 19, followed by a K–5K add on March 20 — two consecutive days, same ticker, total somewhere between 6,000 and $65,000 in a British oil major. No committee overlap flagged. No vote-trade overlap flagged.
Also in that March window: a K–5K Amazon sale on March 9 and the first ORLY sale on March 19. The portfolio that month reads like a reshuffling — out of tech, out of auto parts, into fossil fuels.
The Full Alpha Picture
Across 97 scored trades in our dataset, Jackson has 48 positive outcomes and 49 negative ones. Mean 30-day alpha: essentially zero. A coin flip with paperwork.
The best trades on the books: a September 2025 Robinhood (HOOD) purchase at K–5K that returned 43.2% alpha over 30 days, a January 2026 buy of GE Vernova (GEV) at 5K–$50K that returned 21.1%, and an April 2025 Meta purchase at K–5K that returned 17.0%. None carry committee overlap flags.
The worst: a January 2026 Robinhood sale at K–5K that posted negative 29.5% alpha — he bought HOOD in September 2025 and sold it four months later in a direction that badly underperformed the market. A January 2026 Doximity (DOCS) sale at 5K–$50K came in at negative 23.2%. A January 2026 Palantir sale at 5K–$50K: negative 21.7%.
January 2026 was not a great month to be selling growth names. Three significant exits, three negative alpha outcomes, same calendar month.
The record is 48 for 97. No cherry-picking available here.
The Other Committee Overlap
The Visa sale is not the only committee-overlap trade in the full record. Back in May 2025, Jackson sold $50K–00K in Linde (LIN), flagged under a Chemicals committee overlap. That sale posted negative 5.5% alpha. Two committee-overlap trades in the record, both sales, both negative alpha.
Zero Press, Nine Trades
The one piece of relevant commentary floating online is a Bluesky post linking to a piece Jackson apparently wrote arguing that science is "inherently resilient." It doesn't explain the Visa sale.
He voted against the Save Our Shrimpers Act on May 12 (it passed anyway). He voted against the Veterans 2nd Amendment Protection Act and the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act on May 21 (both passed anyway). On four bills with high market relevance scores on May 20, he was not voting.
The attendance record and the trading record are both public. The full disclosure history is here. The receipts are public. Make of them what you make of them.